Noveris Health Sciences Inc.
MYCOF
$2.00
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6,216.67% | 107.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6,216.67% | 104.48% | |||
| Operating Income | -6,216.67% | -104.48% | |||
| Income Before Tax | -151.30% | 4,127.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -151.30% | 4,127.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -151.30% | 4,127.80% | |||
| EBIT | -6,216.67% | -104.48% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -103.99% | 4,127.42% | |||
| Normalized Basic EPS | 68.86% | -642.80% | |||
| EPS Diluted | -103.99% | 4,127.42% | |||
| Normalized Diluted EPS | 68.86% | -642.80% | |||
| Average Basic Shares Outstanding | 1,185.08% | 0.00% | |||
| Average Diluted Shares Outstanding | 1,185.08% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||